Nonclinical Efficacy Testing
Japanese
MENU
Nonclinical Efficacy Testing » Non-Clinical CROs and Agencies » Nihon Medi-Physics Co.,Ltd.

Nihon Medi-Physics Co.,Ltd.

Table of Contents
Table of Contents

Nihon Medi-Physics Co.,Ltd. handles radiopharmaceuticals, other pharmaceuticals, and regenerative medicine products. This overview summarizes the features of the company’s nonclinical studies, a representative example of disease models, and case examples. Use this information to support selection of a contract research partner.

Features of Nihon Medi-Physics Co.,Ltd.’ Non-Clinical Contract Research Services

Advanced PET imaging technology

Through nonclinical PET imaging studies, Nihon Medi-Physics Co.,Ltd. uses radiolabeled compounds (radioisotopes; RI) to visualize in vivo pharmacokinetics in real time. These studies can evaluate tissue and cellular uptake and metabolism of development candidate compounds. This capability plays an important role in research related to cancer and brain function and can support efficacy assessment and dose selection for new drugs.

Radiopharmaceutical supply

Nihon Medi-Physics Co.,Ltd. manufactures and supplies radiopharmaceuticals used to support the diagnosis of Alzheimer’s disease and Parkinson’s disease, including [18F]flutemetamol and [123I]ioflupane for PET and SPECT imaging. These products support diagnostic accuracy and provide data that can inform new drug development.

Theranostics initiatives

Nihon Medi-Physics Co.,Ltd. also focuses on research and development toward theranostics—the integration of treatment and diagnosis. This approach uses radiopharmaceuticals to support real-time monitoring of a patient’s condition during treatment.

3 Specialized Pre-clinical CROs for Advanced Drug Discovery

Examples of Disease Models Held by Nihon Medi-Physics Co.,Ltd.

No description of the disease models was found.

Examples of Non-Clinical Studies by Nihon Medi-Physics Co.,Ltd.

Evaluation of D2 Receptor Occupancy Using [¹¹C]raclopride

[¹¹C]raclopride, a radiolabeled radiotracer, is used primarily for dopamine D2 receptor studies and diagnostic PET imaging. This study evaluates the extent to which this tracer binds to dopamine D2 receptors in the brain to assess D2 receptor occupancy. A higher occupancy level suggests that the drug is effectively engaging the receptors and is useful for assessing D2 receptor status in studies of psychiatric disorders such as schizophrenia.

Reference: Japan Medifix official websitehttps://www.nmp.co.jp/corpo/business/non-clinical_pet.html

Evaluation of 5-HT2A (Serotonin 2A) Receptor Binding Using [¹⁸F]altanserin

[¹⁸F]altanserin, used in 5-HT2A (serotonin 2A) receptor research and PET imaging, measures and analyzes the degree to which this radiotracer binds to 5-HT2A receptors in the brain. It is useful for quantitative evaluation of the effects of drugs that act on 5-HT2A receptors, such as antidepressants and antipsychotics, and for studying the role of 5-HT2A receptors in psychiatric and neurological disorders such as depression, schizophrenia, and Alzheimer’s disease.

Reference: Japan Medifix official websitehttps://www.nmp.co.jp/corpo/business/non-clinical_pet.html

Nihon Medi-Physics Co.,Ltd. Corporate Information

Nihon Medi-Physics Co.,Ltd. develops, manufactures, and sells radiopharmaceuticals, mainly in the field of nuclear medicine. Its main business areas are PET and SPECT examinations using diagnostic radiopharmaceuticals, as well as cancer treatment using therapeutic radiopharmaceuticals. In addition, the company provides contract services for nonclinical PET imaging studies and contract manufacturing of radiopharmaceuticals.

Address 3-4-10 Shinsuna, Koto-ku, Tokyo, Japan
Tel 03-5634-7006
Website https://www.nmp.co.jp/
Related Articles

3 Recommended Contract Research Organizations
for Non-Clinical Studies
— by Target goal and Expertise

In non-clinical development, the choice of contract research organization shapes the quality of the data and the time it takes to reach the next decision. Below, three CROs are introduced by the type of study they support: pharmacology (efficacy) studies, safety studies, and pharmacokinetic (PK/PD) studies. Each summary describes the services the company offers so that you can match a provider to your target and development objective.

Pharmacology (Efficacy) StudiesDisease-Relevant Models for
Translational Drug Evaluation
SMC Laboratories, Inc.
Reference: SMC Laboratories, Inc. official website (https://www.smccro-lab.com/)

SMC Laboratories, Inc.

SMC Laboratories is a specialized non-clinical CRO focused on in vivo pharmacology and efficacy studies using disease-relevant animal models, particularly in fibrosis, inflammation, metabolic diseases, and oncology.

Areas of Expertise
Disease-Relevant Model Portfolio

SMC Laboratories offers models covering the liver, lung, kidney, intestine, and oncology. Its portfolio includes the proprietary STAM™ model for MASH, fibrosis, and hepatocellular carcinoma.

Study Design Based on Target Biology

Study plans are developed around the target biology, mechanism of action, disease stage, and development objective. Pharmacological endpoints can be combined with histopathology, biomarkers, and disease-specific readouts.

Support from Target Validation to Proof of Concept

With experience from more than 1,000 studies for clients in 30 countries, SMC Laboratories supports programs from target validation and candidate selection through in vivo proof-of-concept studies.

Discuss your target and development objective with SMC Laboratories to identify an appropriate model and study design.
Safety StudiesComprehensive Safety Assessment for
Preclinical Development
Charles River Laboratories
Reference: Charles River Laboratories official website (https://www.criver.com/)

Charles River Laboratories

Charles River provides non-clinical toxicology and safety assessment services for programs ranging from exploratory safety studies to IND-enabling development.

Areas of Expertise
General Toxicology Across Study Designs

Services include single- and repeat-dose toxicology, dose-range finding, and general toxicology studies across multiple species and administration routes.

Non-GLP and GLP Study Support

Charles River supports both non-GLP and GLP studies, allowing sponsors to progress from early safety characterization to studies intended for regulatory submissions.

Integrated IND-Enabling Safety Assessment

Toxicology studies can be integrated with toxicokinetics, clinical pathology, histopathology, and safety pharmacology to support interpretation and IND-enabling safety packages.

Explore Charles River for integrated toxicology and IND-enabling safety assessment.
Pharmacokinetic (PK/PD) StudiesConnecting Drug Exposure with
Pharmacological Response
Inotiv
Reference: Inotiv official website (https://www.inotiv.com/)

Inotiv

Inotiv provides integrated PK/PD, DMPK, and bioanalytical services to characterize drug exposure and its relationship with pharmacological response.

Areas of Expertise
Pharmacokinetic Characterization

PK studies characterize exposure, half-life, clearance, and other pharmacokinetic parameters needed to understand how a candidate behaves in the selected model.

Exposure–Response Evaluation

Pharmacokinetic data can be combined with pharmacodynamic endpoints and bioanalysis to evaluate the relationship between drug exposure and pharmacological response.

Integrated DMPK and Development Support

Integrated DMPK, pharmacology, and safety information supports candidate comparison, dose selection, dosing-frequency optimization, and decisions about subsequent preclinical development.

Explore Inotiv for integrated PK/PD, DMPK, and bioanalytical support.
By Therapeutic Area
Disease Animal Models
and Reviews
Proven Capability, Expertise and Track Record
Top 3 Non-Clinical CRO Services